Kailera Therapeutics, Inc. (KLRA)
The price, the headline numbers and the latest news, in one place.
Kailera Therapeutics, Inc. (KLRA) Stock Price, Analysis & Data
| Bid | 11.16 |
| Market Cap | 2.1B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -292M |
| 0.00 | |
| -2.25 | |
| n/a | |
| -3.78 | |
| P/B (ttm) | 1.88 |
| P/S (ttm) | 0.00 |
| Earnings Date | Oct 29, 2026 |
| Ask | 16.29 |
| Volume | 523,298 |
| Avg. Volume (20D) | 778,782 |
| Open | 15.60 |
| Previous Close | 15.74 |
| Day's Range | 15.60 - 16.44 |
| 52-Week Range | 15.15 - 28.23 |
| Analyst | n/a |
| Price Target | 41 (152.62%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KLRA
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729...
Financial Performance
In 2025, Kailera Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's n/a. Earnings were -148.96M, an increase of undefined%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for KLRA stock is "null". The 12-month stock price forecast is 41, which is upside of 152.62% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.09 misses estimates by -0.33, with -Infinity% YoY decline.
Analysts project revenue of ... Upgrade
